Table 2.

The effect of 4-month liraglutide therapy on evaluated parameters in all patients

Parameters evaluated	Baseline	After 4 months	p
Body weight (kg)	81 ± 16	78 ± 14	< 0.0001*
BMI (kg/m2)	30 ± 5	29 ± 5	< 0.0001*
Waist circumference (cm)	106 ± 13	103 ± 12	< 0.0001*
Fasting glicemia (mmol/l)	9.1 ± 4.0	7.3 ± 2.0	0.0010*
HbA1c (%)	8.4 ± 1.5	6.9 ± 1.1	< 0.0001*
Total cholesterol (mmol/l)	4.7 ± 1.1	4.2 ± 0.9	0.0020*
Triglycerides (mmol/l)	1.9 ± 1.1	1.6 ± 0.7	0.0061*
HDL-cholesterol (mmol/l)	1.1 ± 0.2	1.1 ± 0.2	0.2970
LDL-cholesterol (mmol/l)	2.7 ± 1.1	2.3 ± 0.8	0.0089*
Carotid IMT (mm)	1.13 ± 0.29	0.92 ± 0.24	< 0.0001*

Values in table are presented as the mean ± SD

BMI Body mass index, HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein

*p values that reached statistical significance between baseline and follow-up evaluations